Thrombolysis during Resuscitation for Out-of-Hospital Cardiac Arrest
Open Access
- 18 December 2008
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 359 (25) , 2651-2662
Abstract
Approximately 70% of persons who have an out-of-hospital cardiac arrest have underlying acute myocardial infarction or pulmonary embolism. Therefore, thrombolysis during cardiopulmonary resuscitation may improve survival. In a double-blind, multicenter trial, we randomly assigned adult patients with witnessed out-of-hospital cardiac arrest to receive tenecteplase or placebo during cardiopulmonary resuscitation. Adjunctive heparin or aspirin was not used. The primary end point was 30-day survival; the secondary end points were hospital admission, return of spontaneous circulation, 24-hour survival, survival to hospital discharge, and neurologic outcome. After blinded review of data from the first 443 patients, the data and safety monitoring board recommended discontinuation of enrollment of asystolic patients because of low survival, and the protocol was amended. Subsequently, the trial was terminated prematurely for futility after enrolling a total of 1050 patients. Tenecteplase was administered to 525 patients and placebo to 525 patients; the two treatment groups had similar clinical profiles. We did not detect any significant differences between tenecteplase and placebo in the primary end point of 30-day survival (14.7% vs. 17.0%; P=0.36; relative risk, 0.87; 95% confidence interval, 0.65 to 1.15) or in the secondary end points of hospital admission (53.5% vs. 55.0%, P=0.67), return of spontaneous circulation (55.0% vs. 54.6%, P=0.96), 24-hour survival (30.6% vs. 33.3%, P=0.39), survival to hospital discharge (15.1% vs. 17.5%, P=0.33), or neurologic outcome (P=0.69). There were more intracranial hemorrhages in the tenecteplase group. When tenecteplase was used without adjunctive antithrombotic therapy during advanced life support for out-of-hospital cardiac arrest, we did not detect an improvement in outcome, in comparison with placebo. (ClinicalTrials.gov number, NCT00157261.)Keywords
This publication has 35 references indexed in Scilit:
- A meta-analysis of cardiopulmonary resuscitation with and without the administration of thrombolytic agentsResuscitation, 2006
- Incidence of EMS-treated out-of-hospital cardiac arrest in the United StatesResuscitation, 2004
- Long-term survival and neurological outcome of patients who received recombinant tissue plasminogen activator during out-of-hospital cardiac arrestResuscitation, 2004
- Safety of Thrombolysis during Cardiopulmonary ResuscitationDrug Safety, 2003
- Tissue Plasminogen Activator in Cardiac Arrest with Pulseless Electrical ActivityNew England Journal of Medicine, 2002
- Efficacy and safety of thrombolytic therapy after initially unsuccessful cardiopulmonary resuscitation: a prospective clinical trialThe Lancet, 2001
- Immediate Coronary Angiography in Survivors of Out-of-Hospital Cardiac ArrestNew England Journal of Medicine, 1997
- Thrombolysis using plasminogen activator and heparin reduces cerebral no-reflow after resuscitation from cardiac arrest: An experimental study in the catIntensive Care Medicine, 1996
- Activation of Blood Coagulation After Cardiac Arrest Is Not Balanced Adequately by Activation of Endogenous FibrinolysisCirculation, 1995
- Cause of death in unsuccessful prehospital resuscitationJournal of Internal Medicine, 1991